Short Interest in Inogen, Inc. (NASDAQ:INGN) Decreases By 11.4%

Inogen, Inc. (NASDAQ:INGN - Get Free Report) was the recipient of a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 826,300 shares, a decrease of 11.4% from the October 15th total of 932,600 shares. Based on an average trading volume of 190,100 shares, the days-to-cover ratio is presently 4.3 days.

Inogen Trading Up 1.0 %

INGN stock traded up $0.10 during midday trading on Friday, hitting $10.05. 171,150 shares of the company's stock were exchanged, compared to its average volume of 217,191. The stock has a market capitalization of $239.37 million, a price-to-earnings ratio of -4.47 and a beta of 1.04. The firm has a 50 day moving average price of $9.82 and a 200-day moving average price of $9.53. Inogen has a 12-month low of $4.93 and a 12-month high of $13.33.

Hedge Funds Weigh In On Inogen

Several large investors have recently modified their holdings of the stock. Divisadero Street Capital Management LP raised its stake in Inogen by 682.3% during the second quarter. Divisadero Street Capital Management LP now owns 2,346,766 shares of the medical technology company's stock valued at $19,079,000 after buying an additional 2,046,766 shares in the last quarter. Brown Capital Management LLC lifted its holdings in Inogen by 26.6% in the first quarter. Brown Capital Management LLC now owns 1,975,312 shares of the medical technology company's stock worth $15,941,000 after acquiring an additional 414,903 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Inogen by 312.5% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company's stock worth $1,694,000 after purchasing an additional 132,287 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of Inogen by 29.3% in the 2nd quarter. AQR Capital Management LLC now owns 570,994 shares of the medical technology company's stock valued at $4,642,000 after purchasing an additional 129,307 shares during the period. Finally, Sanctuary Advisors LLC purchased a new position in shares of Inogen during the 2nd quarter valued at $651,000. Institutional investors own 89.94% of the company's stock.

Analyst Upgrades and Downgrades

INGN has been the topic of a number of recent research reports. Needham & Company LLC reissued a "hold" rating on shares of Inogen in a research report on Friday, November 8th. StockNews.com upgraded shares of Inogen from a "hold" rating to a "buy" rating in a report on Tuesday, November 12th.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.